[{"AccountsPayableCurrent_0_Q3_USD":2532000.0,"OtherNonoperatingIncomeExpense_3_Q3_USD":25000.0,"OtherNonoperatingIncomeExpense_1_Q3_USD":1000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_3_Q3_USD":0.0,"OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_3_Q3_USD":-23000.0,"OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1_Q3_USD":-23000.0,"OtherAssetsNoncurrent_0_Q3_USD":2834000.0,"OtherAccruedLiabilitiesCurrent_0_Q3_USD":0.0,"OperatingIncomeLoss_3_Q3_USD":-28439000.0,"PaymentsOfStockIssuanceCosts_3_Q3_USD":2649000.0,"OperatingIncomeLoss_1_Q3_USD":-12427000.0,"OperatingExpenses_1_Q3_USD":12427000.0,"NonoperatingIncomeExpense_3_Q3_USD":-610000.0,"NonoperatingIncomeExpense_1_Q3_USD":1000.0,"NetIncomeLoss_3_Q3_USD":-29049000.0,"NetIncomeLoss_1_Q3_USD":-12426000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-27045000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-56567000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":319166000.0,"OperatingExpenses_3_Q3_USD":28439000.0,"MarketableSecuritiesUnrealizedGainLoss_1_Q3_USD":-23000.0,"PaymentsToAcquireMarketableSecurities_3_Q3_USD":56567000.0,"PreferredStockSharesAuthorized_0_Q3_shares":10000000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":12858574.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":32066089.0,"TemporaryEquityIssuePeriodIncreaseOrDecrease_3_Q3_USD":2592000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q3_USD":174250000.0,"StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1_Q3_USD":185413000.0,"StockholdersEquity_0_Q3_USD":301131000.0,"ShareBasedCompensation_3_Q3_USD":2163000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-60934000.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.0001,"ResearchAndDevelopmentExpense_3_Q3_USD":22365000.0,"RepaymentOfNotesReceivableFromRelatedParties_1_Q3_USD":284000.0,"ProfitLoss_3_Q3_USD":-29049000.0,"ProceedsFromIssuanceOfConvertiblePreferredStock_3_Q3_USD":144652000.0,"ProceedsFromIssuanceInitialPublicOffering_3_Q3_USD":177270000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":2710000.0,"PreferredStockValue_0_Q3_USD":null,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"ResearchAndDevelopmentExpense_1_Q3_USD":9055000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":32066089.0,"MarketableSecuritiesCurrent_0_Q3_USD":56543000.0,"LiabilitiesCurrent_0_Q3_USD":6842000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":245886000.0,"AvailableForSaleSecuritiesAmortizedCost_0_Q3_USD":56566000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q3_USD":23000.0,"AvailableForSaleSecurities_0_Q3_USD":56543000.0,"AssetsFairValueDisclosure_0_Q3_USD":301425000.0,"AssetsCurrent_0_Q3_USD":305139000.0,"Assets_0_Q3_USD":307973000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":4769734.0,"CashAndCashEquivalentsPeriodIncreaseDecrease_3_Q3_USD":235554000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q3_shares":4769734.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":2163000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":1373000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":1373000.0,"AdditionalPaidInCapitalCommonStock_0_Q3_USD":362083000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":-23000.0,"AccruedProfessionalFeesCurrent_0_Q3_USD":1751000.0,"AccruedLiabilitiesCurrent_0_Q3_USD":4310000.0,"AccruedLiabilitiesAndOtherLiabilities_0_Q3_USD":4310000.0,"AmortizationOfDebtDiscountPremium_3_Q3_USD":1000.0,"LossContingencyAccrualAtCarryingValue_0_Q3_USD":0.0,"CommitmentsAndContingencies_0_Q3_USD":null,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-29072000.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":307973000.0,"Liabilities_0_Q3_USD":6842000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":444000.0,"IncreaseDecreaseInOtherOperatingAssets_3_Q3_USD":2834000.0,"IncreaseDecreaseInAccruedLiabilities_3_Q3_USD":1578000.0,"IncreaseDecreaseInAccountsPayable_3_Q3_USD":909000.0,"GeneralAndAdministrativeExpense_3_Q3_USD":6074000.0,"GeneralAndAdministrativeExpense_1_Q3_USD":3372000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-12449000.0,"GainsLossesOnExtinguishmentOfDebt_3_Q3_USD":-580000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_1_Q3_USD":0.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q3_USD":16400000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q3_USD":1679000.0,"EarningsPerShareDiluted_3_Q3_USD":-2.26,"EarningsPerShareDiluted_1_Q3_USD":-0.39,"EarningsPerShareBasic_3_Q3_USD":-2.26,"EarningsPerShareBasic_1_Q3_USD":-0.39,"DefinedContributionPlanEmployerDiscretionaryContributionAmount_3_Q3_USD":0.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_3_Q3_USD":0.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":12858574.0,"Ticker":"NUVL","CIK":"1861560","name":"NUVALENT, INC.","OfficialName":"Nuvalent Inc. Class A Common Stock","form":"10-Q","period":"20210930","fy":"2021.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"574936612.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20211110"}]